Figure 4: Thermal stability (55°C for 1.5 h (b,), 15 h (c, and e,) and 40 h (d,)) studies of rituximab. (b,) - (d,): the samples (MabThera) were diluted prior the thermal treatment, (a,) and (e,): the samples were diluted just before their injections. (a): the sample was kept at room temperature. Conditions: 100 mM phosphate buffer pH 9.3, capillary: 64.5 cm x 50 μm i.d., 60 mbar.s, +10 kV, λ= 200 nm, the samples are diluted with water.